Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Chemotherapy in Neoadjuvant ESCC
NCT05174325Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Pathologic complete remission. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05174325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174325.